Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Blankenstein

Showing results (11-20 of 138) with videos related to

Pageof 14
Sort By:
Nature|September 2, 2005
Sporadic immunogenic tumours avoid destruction by inducing T-cell toleranceGerald Willimsky, Thomas Blankenstein
Cancer Cell|April 20, 2013
It's the peptide-MHC affinity, stupidThomas Kammertoens, Thomas Blankenstein
Trends in Immunology|March 30, 2002
Cross-priming versus cross-tolerance: are two signals enough?Thomas Blankenstein, Thomas Schüler
Advances in Cancer Research|January 9, 2004
Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillanceThomas Blankenstein, Zhihai Qin
Journal of Immunology (Baltimore, Md. : 1950)|April 23, 2003
Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cellsThomas Schüler, Thomas Blankenstein
European Journal of Immunology|July 28, 2009
Making and circumventing tolerance to cancerThomas Kammertoens, Thomas Blankenstein
MMW Fortschritte Der Medizin|April 22, 2022
[Vaginal bleeding - red flags for the general practitioner]Franziska Wagner, Thomas Blankenstein
The Journal of Experimental Medicine|November 19, 2003
Tumor rejection by modulation of tumor stromal fibroblastsThomas Schüler, Sandra Körnig, Thomas Blankenstein
Trends in Molecular Medicine|May 11, 2005
Immunotherapy: target the stroma to hit the tumorThomas Kammertoens, Thomas Schüler, Thomas Blankenstein
The Journal of Experimental Medicine|August 25, 2017
Human TCR-MHC coevolution after divergence from mice includes increased nontemplate-encoded CDR3 diversityXiaojing Chen, Lucia Poncette, Thomas Blankenstein
Pageof 14

Showing results (11-20 of 138) with videos related to

Sort By:
Pageof 14
Nature|September 2, 2005
Sporadic immunogenic tumours avoid destruction by inducing T-cell toleranceGerald Willimsky, Thomas Blankenstein
Cancer Cell|April 20, 2013
It's the peptide-MHC affinity, stupidThomas Kammertoens, Thomas Blankenstein
Trends in Immunology|March 30, 2002
Cross-priming versus cross-tolerance: are two signals enough?Thomas Blankenstein, Thomas Schüler
Advances in Cancer Research|January 9, 2004
Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillanceThomas Blankenstein, Zhihai Qin
Journal of Immunology (Baltimore, Md. : 1950)|April 23, 2003
Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cellsThomas Schüler, Thomas Blankenstein
European Journal of Immunology|July 28, 2009
Making and circumventing tolerance to cancerThomas Kammertoens, Thomas Blankenstein
MMW Fortschritte Der Medizin|April 22, 2022
[Vaginal bleeding - red flags for the general practitioner]Franziska Wagner, Thomas Blankenstein
The Journal of Experimental Medicine|November 19, 2003
Tumor rejection by modulation of tumor stromal fibroblastsThomas Schüler, Sandra Körnig, Thomas Blankenstein
Trends in Molecular Medicine|May 11, 2005
Immunotherapy: target the stroma to hit the tumorThomas Kammertoens, Thomas Schüler, Thomas Blankenstein
The Journal of Experimental Medicine|August 25, 2017
Human TCR-MHC coevolution after divergence from mice includes increased nontemplate-encoded CDR3 diversityXiaojing Chen, Lucia Poncette, Thomas Blankenstein
Pageof 14